Listen to The Lancet Neurology

Rustam Al-Shahi Salman joins Senior Editor Sarah Passey to discuss the COCROACH meta-analysis findings, published in the December issue of The Lancet Neurology , of the effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage.

Njideka Okubadejo and Mie Rizig join The Lancet Neurology to discuss their comprehensive genome-wide assessment in African and African admixed individuals with the aim of developing a better understanding of the genetic architecture of Parkinson's disease in these underserved populations.

Anthony Feinstein (University of Toronto and Sunnybrook Health Sciences Centre, Toronto, Canada) discusses CogEx, a randomised trial of cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis. The Article is published in the October issue of The Lancet Neurology .

William Jagust (University of California in Berkeley, CA, USA) talks to Senior Editor Sarah Passey about the complex pathway between amyloid β and cognition, and implications for therapy for people with Alzheimer’s disease. His Personal View on this topic is published in the September issue of The Lancet Neurology .

Stephen Strittmatter (Yale School of Medicine, CT, USA) discusses his first-in-human and randomised trial of a soluble Nogo-receptor-Fc decoy in patients with chronic cervical spinal cord injury. The Article is published in the August issue of The Lancet Neurology .

Benzi Kluger (University of Rochester Medical Center, Rochester, NY, USA), Claire Creutzfeldt (University of Washington, Seattle, WA, USA), and Malenna Sumrall (University of Colorado Anschutz Medical Campus, Aurora, CO, USA) join Jonathan Blott to discuss palliative care for individuals with neurological diseases, exploring the challenges and opportunities in enhancing the quality of life for tho...

Karen Duff and Connor Langworth-Green (University College London, London, UK) discuss tauopathies and the chronic effects of inflammation on this group of disorders. Their Personal View on this topic is published in the May issue of The Lancet Neurology .

Kerstin Hellwig (Ruhr University Bochum, Bochum, Germany) discusses family planning considerations in multiple sclerosis. This Review is published in the April issue of The Lancet Neurology .

Geraldine Dawson (Duke University School of Medicine, NC, USA) discusses the latest advances and ongoing challenges in prediction of autism during infancy. This Review is published in the March issue of The Lancet Neurology .

Ellisiv Mathiesen (The University of Tromsø – the Arctic University of Norway, Tromsø, Norway) discusses the findings of the TWIST trial, which investigated the use of tenecteplase for patients with wake-up stroke who were selected for treatment by non-contrast CT. This Fast-track Article is published in the February issue of The Lancet Neurology .

Beau Ances (Washington University in St Louis, MO, USA) discusses recent research on amyloid biomarkers in people with genetic forms of Alzheimer’s disease; his Article is published in the January issue of The Lancet Neurology .

Axel Petzold (National Hospital for Neurology and Neurosurgery and Moorfields Eye Hospital, London, UK, and Amsterdam University Medical Center, Amsterdam, Netherlands) discusses a Position Paper, published in the December issue of The Lancet Neurology , which sets out new criteria for the diagnosis and classification of optic neuritis.

Maeike Zijlmans (University Medical Center Utrecht, Utrecht, Netherlands) discusses recent research on tailoring of epilepsy surgery with biomarkers on intraoperative electrocorticography, and describes some of the challenges of this technique and what the future steps are for the field.

Jerome Siegel (University of California, Los Angeles, CA, USA) discusses sleep research in hunter-gatherer populations and what we can learn from the sleep habits of various species; his Review is published in the October issue of The Lancet Neurology , which is the fourth paper in The Lancet’ s Series on sleep and sleep disorders.

Laurent Servais and Dora Markati (both from the University of Oxford, UK) discuss emerging therapies for Duchenne muscular dystrophy; their Review is published in the September issue of The Lancet Neurology.

Andreas Charidimou (Massachusetts General Hospital, Boston, MA, USA) discusses an international collaborative study that presents new Boston criteria for diagnosis of cerebral amyloid angiopathy; the Article is published in the August issue of The Lancet Neurology .

Sarah Tabrizi (UCL Queen Square Institute of Neurology, London, UK) and Cristina Sampaio (CHDI Foundation, Princeton, NJ, USA) discuss two papers on Huntington’s disease published in the July issue of The Lancet Neurology : a Position Paper outlining a new classification of the disease, called the Huntington’s Disease Integrated Staging System, and a Personal View on potential disease-modifying th...

Mark Hallett (National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA) discusses his Review, published in the June issue of The Lancet Neurology , on functional neurological disorder, and talks about new subtypes of this disorder, diagnostic challenges, and how education is important.

Eva Feldman (University of Michigan, Ann Arbor, USA) discusses the latest advances in the genetics, risk factors, pathophysiology, therapeutic development, and the diagnosis and prognosis of amyotrophic lateral sclerosis; the Series is published in the May issue of The Lancet Neurology.

Estrella Morenas-Rodriguez and Christian Haass (German Centre for Neurodegenerative Diseases, Munich, Germany) discuss their recent research, published in the April issue of The Lancet Neurology , on soluble TREM2 and its association with Alzheimer’s disease biomarkers and cognition.

John Collinge (MRC Prion Unit, University College London, London, UK) discusses a first-in-human treatment programme to give PRN100, an anti-prion-protein monoclonal antibody, to patients with Creutzfeldt–Jakob disease; the report is published in the April issue of The Lancet Neurology .

Alexandra Durr (Paris Brain Institute, Pitié-Salpêtrière Paris, France) discusses the ATRIL study, a randomised trial of riluzole in patients with spinocerebellar ataxia type 2, which is published in the March issue of The Lancet Neurology.

Giuseppe Citerio (University of Milano-Bicocca, Milan, Italy) discusses the implications of a study from the CENTER-TBI project of the effect of frailty on 6-month outcome after traumatic brain injury, which is published in the February issue of The Lancet Neurology .

Alberto Costa (Case Western Reserve University, Cleveland, OH, USA) discusses his study on the use of memantine in adolescents and young adults with Down syndrome, which is published in the January issue of The Lancet Neurology .

Olivier Rascol (Toulouse University, France) discusses the uses of amantadine in the treatment of patients with movement disorders, which are the focus of his Personal View in the December issue of The Lancet Neurology.